Invesco Ltd. Sells 104,445 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Invesco Ltd. reduced its stake in BioCryst Pharmaceuticals by 9.7%, selling 104,445 shares and holding 968,155 shares at the end of the first quarter.
• Analysts are generally bullish on BioCryst Pharmaceuticals, with nine analysts rating it as a "Buy" and target prices ranging from $13 to $30, leading to a consensus target price of $16.70.
• BioCryst Pharmaceuticals reported a 49.5% year-over-year increase in revenue, totaling $163.35 million for the last quarter, while earnings per share reached $0.15, surpassing expectations.

Invesco Ltd. lowered its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 9.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 968,155 shares of the biotechnology company's stock after selling 104,445 shares during the period. Invesco Ltd. owned approximately 0.46% of BioCryst Pharmaceuticals worth $7,261,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Allianz Asset Management GmbH increased its holdings in shares of BioCryst Pharmaceuticals by 9.6% in the first quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company's stock worth $103,000 after buying an additional 1,200 shares during the period. SG Americas Securities LLC grew its stake in shares of BioCryst Pharmaceuticals by 5.2% in the first quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company's stock worth $326,000 after purchasing an additional 2,146 shares during the last quarter. Mariner LLC grew its stake in shares of BioCryst Pharmaceuticals by 32.1% in the fourth quarter. Mariner LLC now owns 13,258 shares of the biotechnology company's stock worth $100,000 after purchasing an additional 3,224 shares during the last quarter. Quantinno Capital Management LP grew its stake in shares of BioCryst Pharmaceuticals by 38.2% in the fourth quarter. Quantinno Capital Management LP now owns 14,828 shares of the biotechnology company's stock worth $112,000 after purchasing an additional 4,097 shares during the last quarter. Finally, Headlands Technologies LLC bought a new stake in shares of BioCryst Pharmaceuticals in the first quarter worth about $32,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Trading Down 1.9%

BioCryst Pharmaceuticals stock traded down $0.16 during trading hours on Friday, hitting $8.31. 2,313,769 shares of the stock traded hands, compared to its average volume of 2,973,741. The firm's 50-day moving average price is $8.67 and its two-hundred day moving average price is $8.78. The company has a market cap of $1.74 billion, a PE ratio of -46.16, a PEG ratio of 1.89 and a beta of 1.10. BioCryst Pharmaceuticals, Inc. has a one year low of $6.01 and a one year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to the consensus estimate of $149.59 million. The business's revenue was up 49.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.06) earnings per share. On average, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Theresa Heggie sold 70,000 shares of the business's stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the sale, the director directly owned 65,352 shares of the company's stock, valued at $556,145.52. The trade was a 51.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 5.10% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on BCRX shares. Needham & Company LLC reissued a "buy" rating and issued a $17.00 target price on shares of BioCryst Pharmaceuticals in a research note on Monday, August 4th. Royal Bank Of Canada restated an "outperform" rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Wedbush upped their target price on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a report on Monday, June 30th. JPMorgan Chase & Co. upped their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a report on Tuesday, May 6th. Finally, HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $16.70.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.